-
公开(公告)号：EP3233858A1
公开(公告)日：2017-10-25
申请号：EP15870725.7
申请日：2015-12-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： SILIPHAIVANH, Phieng , METHOT, Joey , LIPFORD, Kathryn Ann , MOLINARI, Danielle , SLOMAN, David, L. , WITTER, David , ZHOU, Hua , BOYCE, Christopher , HUANG, Xianhai , LIM, Jongwon , GUERIN, David , KARUNAKARAN, Ganesh Babu , BAKSHI, Raman Kumar , LIU, Ziping , FU, Jianmin , WAN, Zhilong , LIU, Wei
IPC: C07D471/04
Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
Abstract translation: 本发明提供了作为ERK2抑制剂的式（I）化合物或其药学上可接受的盐，酯和前药。 本发明还提供了包含有效量的至少一种式（I）化合物和药学上可接受的载体的药物组合物。 本发明还提供了药物组合物，其包含有效量的至少一种式（I）化合物和有效量的至少一种其他药物活性成分（例如化疗剂）和药学上可接受的载体 。
-
Patent Agency Ranking
公开(公告)号：EP2900223B1
公开(公告)日：2017-10-25
申请号：EP13841687.0
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： WILSON, Kevin, J. , WITTER, David, J. , DANIELS, Matthew, H. , ANGELES, Angie, R. , SILIPHAIVANH, Phieng , SLOMAN, David , O'BOYLE, Brendan , FALCONE, Danielle , WHITE, Catherine , FERGUSON, Ron , ZHOU, Wei , LIPFORD, Kathryn , MANSOOR, Umar Faruk , FEVRIER, Salem , HUANG, Xianhai , KURUKULASURIYA, Ravi , RICHARD, Judson, E. , TANG, Shuyi , BOYCE, Christopher , KOZLOWSKI, Joseph , BAKSHI, Raman Kumar , KARUNAKARAN, Ganesh Babu
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
-
公开(公告)号：EP3233858B1
公开(公告)日：2019-10-30
申请号：EP15870725.7
申请日：2015-12-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： SILIPHAIVANH, Phieng , METHOT, Joey , LIPFORD, Kathryn Ann , MOLINARI, Danielle , SLOMAN, David, L. , WITTER, David , ZHOU, Hua , BOYCE, Christopher , HUANG, Xianhai , LIM, Jongwon , GUERIN, David , KARUNAKARAN, Ganesh Babu , BAKSHI, Raman Kumar , LIU, Ziping , FU, Jianmin , WAN, Zhilong , LIU, Wei
IPC: C07D471/04
-
公开(公告)号：EP2900223A1
公开(公告)日：2015-08-05
申请号：EP13841687.0
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： WILSON, Kevin, J. , WITTER, David, J. , DANIELS, Matthew, H. , ANGELES, Angie, R. , SILIPHAIVANH, Phieng , SLOMAN, David , O'BOYLE, Brendan , FALCONE, Danielle , WHITE, Catherine , FERGUSON, Ron , ZHOU, Wei , LIPFORD, Kathryn , MANSOOR, Umar Faruk , FEVRIER, Salem , HUANG, Xianhai , KURUKULASURIYA, Ravi , RICHARD, Judson, E. , TANG, Shuyi , BOYCE, Christopher , KOZLOWSKI, Joseph , BAKSHI, Raman Kumar , KARUNAKARAN, Ganesh Babu
IPC: A61K9/66 , A61K31/00 , A61K31/4545
CPC classification number: A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds offormula (1.0).
-
公开(公告)号：EP2900241B1
公开(公告)日：2018-08-08
申请号：EP13840779.6
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： WILSON, Kevin, J. , WITTER, David, J. , SILIPHAIVANH, Phieng , LIPFORD, Kathryn , SLOMAN, David , FALCONE, Danielle , O'BOYLE, Brendan , MANSOOR, Umar Faruk , LIM, Jongwon , METHOT, Joey, L. , BOYCE, Christopher , CHEN, Lei , DANIELS, Matthew, H. , FEVRIER, Salem , HUANG, Xianhai , KURUKULASURIYA, Ravi , TONG, Ling , ZHOU, Wei , KOZLOWSKI, Joseph , MALETIC, Milana, M. , SHINKRE, Bidhan, A. , THATAI, Jayanth Thiruvellore , BAKSHI, Raman Kumar , KARUNAKARAN, Ganesh Babu
IPC: C07D471/04 , C07D471/16 , C07D498/16 , C07D519/00 , A61K31/437 , A61K31/4375 , A61P35/00
CPC classification number: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
-
公开(公告)号：EP2900241A2
公开(公告)日：2015-08-05
申请号：EP13840779.6
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： WILSON, Kevin, J. , WITTER, David, J. , SILIPHAIVANH, Phieng , LIPFORD, Kathryn , SLOMAN, David , FALCONE, Danielle , O'BOYLE, Brendan , MANSOOR, Umar Faruk , LIM, Jongwon , METHOT, Joey, L. , BOYCE, Christopher , CHEN, Lei , DANIELS, Matthew, H. , FEVRIER, Salem , HUANG, Xianhai , KURUKULASURIYA, Ravi , TONG, Ling , ZHOU, Wei , KOZLOWSKI, Joseph , MALETIC, Milana, M. , SHINKRE, Bidhan, A. , THATAI, Jayanth Thiruvellore , BAKSHI, Raman Kumar , KARUNAKARAN, Ganesh Babu
IPC: A61K31/4745
CPC classification number: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
